JWH-268

JWH-268 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent agonist of the cannabinoid receptors. It was developed by John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.

Chemical Structure and Properties

JWH-268 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. Its chemical structure consists of a naphthalene group attached to a methanone bridge, which is further connected to an indole group with a pentyl chain at the nitrogen atom. The IUPAC name for JWH-268 is (1-pentyl-1H-indol-3-yl)-1-naphthalenylmethanone.

The molecular formula of JWH-268 is C24H23NO, and it has a molar mass of 341.45 g/mol. The compound is typically synthesized in a laboratory setting and is not found naturally.

Pharmacology

JWH-268 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a higher affinity for the CB1 receptor. This receptor is primarily found in the central nervous system and is responsible for the psychoactive effects of cannabinoids. The activation of CB1 receptors by JWH-268 can lead to effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Legal Status

The legal status of JWH-268 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. In the United States, JWH-268 and other synthetic cannabinoids have been placed under Schedule I of the Controlled Substances Act, making their manufacture, distribution, and possession illegal without a license.

Research and Applications

JWH-268, like other synthetic cannabinoids, has been used in scientific research to study the endocannabinoid system and the effects of cannabinoid receptor activation. However, due to its potential for abuse and adverse effects, its use is limited to controlled laboratory settings.

Health Effects and Risks

The use of JWH-268 and similar synthetic cannabinoids can pose significant health risks. These compounds can cause a range of adverse effects, including tachycardia, hypertension, hallucinations, and psychosis. The variability in potency and purity of synthetic cannabinoids further increases the risk of overdose and severe health consequences.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman
• Naphthoylindole
• Endocannabinoid system